Clinical series · PMID 15881150
Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina — VialBase Research
Primary human evidence for Retinalamin in hereditary retinal degeneration; cited in the clinical-evidence table.
Last updated · 2005 · Khvatova AV et al. · Vestn Oftalmol
Key findings
- Polypeptide bioregulators including Retinalamin were used in hereditary retinal abiotrophies (retinitis pigmentosa and related degenerations)
- Reported stabilization or improvement of visual function in a difficult-to-treat category with limited standard-of-care options
- Human clinical evidence, Russian ophthalmology practice
Polypeptide bioregulators in hereditary retinal abiotrophy (PMID: 15881150)
Summary
A clinical series applying polypeptide bioregulators (including Retinalamin) to hereditary retinal abiotrophies reported stabilization or improvement of visual function — a category (retinitis pigmentosa and relatives) where conventional options are limited.
Relevance
This is the main human dataset behind Retinalamin‘s use in hereditary retinal degenerations. It is a clinical series from Russian practice, not a randomized controlled trial.
See Also
- Parent compound: Retinalamin